An alternative to the Thorough QT Trial-EPQT

Presented by PRA Health Sciences and iCardiac Technologies 

Tuesday, June 20, 2017 | 10:00 am - 3:00 pm

Hotel The Peninsula 19
Avenue Kleber 75116 Paris France

iCardiac and PRA Health Sciences, an iCardiac Certified Partner, present an “Early Drug Development Workshop: an alternative to the Thorough QT Trial-EPQT.” Dr. Borje Darpo, iCardiac and Dr. Thijs van Iersel, PRA will discuss a new standard for cardiac safety, early precision QT, and the importance of accurate data collection. Dr. Darpo will detail significant regulatory changes and the benefits of using EPQT during drug development while Dr. van Iersel will offer insight on the practical rollout of EPQT. Finally, a case study demonstrating real-world application will be presented by Geert Winnen, Clinical Project Leader with Mithra Pharmaceuticals. 



Hôtel The Peninsula Paris

Perfectly situated at 19 Avenue Kléber, just steps from the Arc de Triomphe, The Peninsula sits in the heart of Paris within walking distance of some of the world’s most famous monuments, museums and luxury shopping districts.

Let Us Know You're Coming

Please fill out the form below to confirm your attendance. Spaces are limited and only available to representatives of pharmaceutical and biotech companies.

Please fill out the form below to confirm your attendance by June 12, 2017

Still have questions?

Should you have questions regarding the event or need to change your attendance status, please contact us.